Sickle Cell Disease (SCD) is a genetic blood disorder that affects millions of people worldwide. Between 2010 and 2050, an estimated 14 million babies will be affected globally, with the vast majority born in low- and middle-income countries (LMICs).
This staggering figure highlights the urgent need for global action to improve access to care and ensure equitable treatment for those living with SCD.
The Burden of Sickle Cell Disease
SCD disproportionately impacts LMICs, where resources for diagnosis, prevention, and treatment are often limited. Each year, over 300,000 babies are born with SCD, and Sub-Saharan Africa bears the highest burden. In this region, 50–90% of children with SCD do not reach their fifth birthday due to inadequate access to diagnosis and treatment.
Globally, 5% of the population are healthy carriers of the SCD gene, with prevalence reaching as high as 25% in some regions. Despite the widespread impact of SCD, many affected individuals lack access to essential medicines and basic healthcare, exacerbating the disease’s devastating effects on families and communities.
The Clinical Impact of Hydroxyurea
Hydroxyurea, a cornerstone treatment for SCD in high-income countries, offers a lifeline to patients. This medication reduces complications such as pain crises, acute chest syndrome, and the need for blood transfusions while enhancing the overall quality of life for patients.
Notably, Hydroxyurea is listed on the World Health Organization’s (WHO) Essential Medicines List (EML) for its critical role in treating SCD. The inclusion on the WHO EML underscores its safety, efficacy, and importance in addressing a significant global health burden.
However, despite its recognised value, access to this life-saving medication remains critically limited in LMICs, where the majority of SCD patients reside.
A Step Forward: Ensuring Equitable Access to SCD Treatment
Bridging the treatment gap for SCD is essential to achieving equitable health outcomes. Key barriers include limited availability of essential treatments like Hydroxyurea, which are often unavailable or unaffordable in resource-limited settings.
SCD may pose significant challenges, but the solutions are within reach. Through collaborative efforts, equitable access to essential treatments like Hydroxyurea can be achieved, improving the lives of millions affected by this devastating disease.
NCDconnect is one of the solutions addressing these inequities. As a digital procurement platform dedicated to improving access to medicines and medical devices for noncommunicable diseases (NCDs), it includes Hydroxyurea in its comprehensive product portfolio. By streamlining supply chains and consolidating demand, NCDconnect supports healthcare organisations in ensuring this life-saving medication reaches the communities that need it most.